The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Clinical trial NCT06254690 · RECRUITING
Trial details
- NCT number
- NCT06254690
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-01
- Primary completion
- 2026-11-01
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.